Robert E. Waltermire - 17 Jan 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 17 Jan 2025
Net transaction value: -$120,847
SEC form: 4
Accepted by SEC: 17 Jan 2025, 19:08:21 UTC
Prior SEC filing: 18 Jun 2024
Next SEC filing: 27 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 17 Jan 2025.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jan 2025, 19:08.

Change

Previous filing in this sequence was filed on 18 Jun 2024.
Current net transaction value: -$120,847.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Sale

Transaction value: $120,847
Shares: -442
Change %: -8%
Price: $273.41
Shares after: 5,058
Date: 17 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.